scholarly journals cfDNA in pancreatic neuroendocrine carcinoma management with Cushing’s syndrome

2021 ◽  
Author(s):  
Laura Gerard ◽  
David Barthelemy ◽  
Arnaud Gauthier ◽  
Valerie Hervieu ◽  
Jonathan Lopez ◽  
...  

We report a case of metastatic pancreatic neuroendocrine carcinoma associated with paraneoplastic Cushing’s syndrome, successively treated with five lines of treatment (platin-etoposide, LV5FU2-dacarbazine, Folfirinox, pembrolizumab, and paclitaxel) and anti-secretory treatment. Circulating-free DNA (cfDNA) was analysed at each morphological evaluation starting from the second-line treatment. cfDNA changes were well-correlated with the disease course, and cfDNA may be used as a predictive marker and/or an early marker of response. In addition, absolute count of atypical cells was elevated upon disease progression.

2017 ◽  
Author(s):  
Gulchekhra Narimova ◽  
Zamira Yusupovna ◽  
Ravshan Fayzullaev ◽  
Iskandar Arifjanov

Endocrine ◽  
2020 ◽  
Vol 67 (2) ◽  
pp. 318-320
Author(s):  
Luigi Di Filippo ◽  
Giordano Vitali ◽  
Gianluca Taccagni ◽  
Federica Pedica ◽  
Giulia Guaschino ◽  
...  

2010 ◽  
Vol 26 (1) ◽  
pp. 46-48
Author(s):  
Narasingarao Pantula ◽  
Ramesh Jayanthy ◽  
Vasani Kannan ◽  
Satish Kumar Missula

2001 ◽  
Vol 197 (2) ◽  
pp. 129-133
Author(s):  
Mine Hekimgil ◽  
Fusun Hamulu ◽  
Ufuk Çagirici ◽  
Bulent Karabulut ◽  
A. Gokhan Ozgen ◽  
...  

2000 ◽  
Vol 11 (4) ◽  
pp. 359-364 ◽  
Author(s):  
Isabelle Valo ◽  
Vincent Rohmer ◽  
Serge Guyétant ◽  
Jean-François Martin ◽  
Sophie Venault ◽  
...  

2018 ◽  
Vol 6 (5) ◽  
pp. 851-854 ◽  
Author(s):  
Alfredo Adolfo Reza-Albarrán ◽  
Gerson Geovany Andino Ríos ◽  
Laura Gabriela Gómez Herrera

Sign in / Sign up

Export Citation Format

Share Document